GSA Capital Partners LLP Sells 2,510 Shares of Guardant Health, Inc. (NASDAQ:GH)

GSA Capital Partners LLP reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 13.2% in the third quarter, Holdings Channel.com reports. The institutional investor owned 16,489 shares of the company’s stock after selling 2,510 shares during the period. GSA Capital Partners LLP’s holdings in Guardant Health were worth $378,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Guardant Health by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock valued at $102,000 after purchasing an additional 796 shares in the last quarter. JNBA Financial Advisors purchased a new stake in shares of Guardant Health in the third quarter worth $26,000. Ashton Thomas Securities LLC bought a new position in shares of Guardant Health during the third quarter valued at $34,000. Quarry LP purchased a new position in shares of Guardant Health in the 2nd quarter worth about $44,000. Finally, Green Alpha Advisors LLC raised its position in shares of Guardant Health by 23.6% in the 3rd quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company’s stock worth $201,000 after purchasing an additional 1,674 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Trading Up 1.3 %

Guardant Health stock opened at $31.09 on Friday. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $37.04. The firm has a market capitalization of $3.84 billion, a price-to-earnings ratio of -7.31 and a beta of 1.11. The firm has a 50 day moving average of $24.00 and a 200 day moving average of $26.71.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health’s revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.73) earnings per share. As a group, research analysts predict that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at $228,675.20. This trade represents a 27.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of analyst reports. Citigroup raised their price objective on shares of Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Leerink Partners decreased their price objective on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. The Goldman Sachs Group boosted their price target on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. UBS Group raised their price target on shares of Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 21st. Finally, BTIG Research increased their price objective on shares of Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.